Home

About

Advanced Search

Browse by Discipline

Scientific Societies

E-print Alerts

Add E-prints

E-print Network
FAQHELPSITE MAPCONTACT US


  Advanced Search  

 
[CANCER RESEARCH 63, 68646869, October 15, 2003] Subcellular Localization of Radiolabeled Somatostatin Analogues: Implications for
 

Summary: [CANCER RESEARCH 63, 68646869, October 15, 2003]
Subcellular Localization of Radiolabeled Somatostatin Analogues: Implications for
Targeted Radiotherapy of Cancer1
Mu Wang, Amy L. Caruano, Michael R. Lewis,2
Laura A. Meyer, Robert P. VanderWaal, and Carolyn J. Anderson3
Mallinckrodt Institute of Radiology [M. W., A. L. C., M. R. L., L. A. M., C. J. A.], and Department of Radiation Oncology [R. P. V.], Washington University School of Medicine, St.
Louis, Missouri 63110
ABSTRACT
Copper-64 (T1/2 12.7 h; , 17.4%; , 39%) has been used both in
positron emission tomography imaging and in radiotherapy. Copper-64
radiopharmaceuticals have shown tumor growth inhibition with a relatively
low radiation dose in animal models; however, the mechanism of cytotoxicity
has not been fully elucidated. These studies incorporate the use of somatosta-
tin receptor-positive AR42J rat pancreatic tumor cells in vitro to understand
the cell killing mechanism of 64
Cu by focusing on subcellular distribution of
the somatostatin analogues 64
Cu-labeled 1,4,8,11-tetraazacyclotetradecane-
1,4,8,11-tetraacetic acid-octreotide (64
Cu-TETA-OC) and 111

  

Source: Anderson, Carolyn J. - Department of Molecular Biology and Pharmacology, Washington University in St. Louis

 

Collections: Biology and Medicine